Transcranial Magnetic Stimulation (TMS) therapy was initially cleared by the USA Food and Drug Administration (FDA) in 2008 as a treatment for adults with major depression who have failed to respond to at least one antidepressant. 

Specifically, Magstim holds six 510(k) clearances for its TMS therapy systems including the 3-minute, 19-minute and 37.5-minute treatment sessions as well as the first FDA-cleared navigation system designed for the clinical setting.

Since 2010, TMS therapy has been recommended by the American Psychiatric Association for the treatment of major depressive disorder and is covered by most major insurers including Medicare. Additionally more states are covering TMS therapy under their Medicaid policy.